The technology, called PGA (Patient-derived Gene expression-informed Anticancer drug efficacy), could “help health professionals to match individuals to the right drugs and drug combinations,” said OncoDxRx. “This increases the probability of response to the drug and, as we have shown, improve survival in a prospective analysis.”

The company explained that PGA works on an individual and their cancer. It is created from gene expression data from thousands of patients with cancer who have been treated in different ways and considers information about the patient, their demographic profile, the type of cancer that they have, including molecular data on their tumor, and any potential drug they may be exposed to.

“The great thing about using this technology is that the real-world and real-time patient-derived gene signature, the digital data fusion and analytics, and it also allows you to follow the patient’s cancer journey,” OncoDxRx said.

“We see far too many people not benefiting from precision therapy in clinic and we wanted a way that we could get better insight into who will and will not respond and which drug had a higher chance of working,” the company said. “At the moment there is no biomarker that we can use to predict drug efficacy/response for those non-responders to precision medicine.”

OncoDxRx’s published clinical study showed that when patients received the treatment recommended by PGA test results, they had better outcomes, i.e., longer progression-free and overall survival, compared to the patients without PGA support.

OncoDxRx said: “We are excited to apply this type of technology across different tumor types to predict patients’ responses to ALL AVAILABLE CANCER DRUGS and the results are encouraging.”

“This technology means that researchers can predict drug efficacy at a much earlier stage in drug development and they can run the PGA assay multiple times to test out different combinations in different patients and maximize the likelihood of success.”

“We have developed and validated this technology so that it can predict treatment response for individual patients in the clinic and help doctors understand which drugs will or will not be helpful.”

OncoDxRx hopes that, “PGA can be routinely used to delivering precision medicine in the clinic or at the bedside by predicting individual’s response to cancer treatment, especially for those patients with limited treatment options.”

Indeed, once the patient’s own gene signature has been generated, PGA can create predictions within hours, making it feasible for point-of-care use.

OncoDxRx also anticipate that pharma and biotech companies will use PGA to support development of their novel compounds from the laboratory to phase I trials, and at the concept point of developing clinical studies.